Table 2 Parameters in patients treated with dose personalization based on quantification of Escitalopram plasma levels.
Readout | Timepoint | Inadequate drug level | Unadjusted dose | Adjusted dose | P-value |
|---|---|---|---|---|---|
HAM-D | Baseline | 22.5 ± 3.2 (100%) | 21.8 ± 2.2 (100%) | 21.0 ± 1.2 (100%) | < 0.0001 |
4 weeks | 16.4 ± 3.1 (73 ± 14%) | 11.9 ± 3.7 (54 ± 17%) | 13.4 ± 1.7 (62 ± 8%) | ||
8 weeks | 11.4 ± 3.6 (50 ± 16%) | 7.1 ± 3.3 (32 ± 15%) | 10.6 ± 1.9 (52 ± 9%) | ||
HAM-A | Baseline | 24.1 ± 4.7 (100%) | 24.2 ± 3.1 (100%) | 24.1 ± 2.1 (100%) | < 0.0001 |
4 weeks | 17.3 ± 5.2 (71 ± 22%) | 14.4 ± 4.9 (58 ± 20%) | 16.1 ± 2.4 (67 ± 10%) | ||
8 weeks | 12.4 ± 4.7 (50 ± 20%) | 8.8 ± 4.0 (37 ± 17%) | 13.4 ± 2.4 (54 ± 10%) | ||
CGI-S | Baseline | 4.7 ± 0.4 | 4.3 ± 0.3 | 4.4 ± 0.2 | < 0.0001 |
4 weeks | 3.8 ± 0.8 | 2.6 ± 0.7 | 3.0 ± 0.3 | ||
8 weeks | 2.8 ± 0.9 | 1.8 ± 0.5 | 2.4 ± 0.3 | ||
CGI-I | 4 weeks | 2.5 ± 0.7 | 1.8 ± 0.6 | 2.1 ± 0.3 | < 0.0001 |
8 weeks | 1.8 ± 0.6 | 1.4 ± 0.4 | 1.9 ± 0.3 | ||
QTc interval (ms) | Baseline | 392.6 ± 10.1 | 402.9 ± 8.3 | 399.5 ± 4.9 | 0.0041 |
4 weeks | 395.1 ± 9.9 (2.5 ± 7.1) | 406.2 ± 8.2 (3.2 ± 7.5) | 399.5 ± 4.7 (0.0 ± 3.6) | ||
8 weeks | 395.3 ± 8.9 (2.7 ± 10) | 410.2 ± 7.4 (7.2 ± 6.6) | 406.2 ± 4.4 (6.7 ± 3.9) | ||
Heart rate (bpm) | Baseline | 75.5 ± 9.6 | 69.8 ± 4.8 | 76.2 ± 3.5 | 0.013 |
4 weeks | 69.7 ± 7.0 (−5.8 ± 6.4) | 69.2 ± 5.2 (−0.7 ± 5.3) | 73.4 ± 3.5 (−2.8 ± 3.2) | ||
8 weeks | 70.5 ± 6.0 (−4.9 ± 7.8) | 68.1 ± 5.0 (−1.8 ± 4.9) | 72.3 ± 2.8 (−3.9 ± 2.8) | ||
Mean arterial pressure (mmHg) | Baseline | 90.2 ± 4.8 | 91.9 ± 5.0 | 89.3 ± 2.4 | 0.069 |
4 weeks | 88.4 ± 4.4 (−1.8 ± 3.3) | 88.9 ± 5.5 (−3.0 ± 5.1) | 89.8 ± 2.2 (0.5 ± 2.3) | ||
8 weeks | 88.0 ± 5.3 (−2.2 ± 4.6) | 87.9 ± 4.4 (−3.9 ± 4.3) | 88.9 ± 2.8 (−0.4 ± 2.6) |
